Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Merck_KGaA's_biosimilars_business
gptkb:Upjohn_division_of_Pfizer |
| gptkbp:CEO |
gptkb:Heather_Bresch
|
| gptkbp:collaboratedWith |
Upjohn
|
| gptkbp:employees |
over 35,000
|
| gptkbp:focus |
Affordable healthcare
|
| gptkbp:founded |
1961
|
| gptkbp:founder |
Milton_P._H._H._Mylan
|
| gptkbp:headCoach |
35,000+
|
| gptkbp:headquarters |
gptkb:Canonsburg,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mylan Pharmaceuticals Inc.
|
| gptkbp:market |
$9.5 billion (2020)
|
| gptkbp:operatesIn |
Global market
|
| gptkbp:partnerships |
gptkb:Pfizer
|
| gptkbp:products |
gptkb:Metformin
gptkb:Simvastatin gptkb:Baclofen gptkb:Esomeprazole gptkb:Zolpidem Lisinopril Branded drugs Ciprofloxacin Levothyroxine Duloxetine Atenolol Dexamethasone Amoxicillin Carbamazepine Valproate Fentanyl Lipitor Bupropion Fluoxetine Mirtazapine Quetiapine Risperidone Sertraline Venlafaxine Ranitidine Omeprazole EpiPen Clonazepam Tramadol Amlodipine Hydrochlorothiazide Citalopram Furosemide Gabapentin Montelukast Tamsulosin Topiramate Generic_drugs Atenolol/Chlorthalidone |
| gptkbp:revenue |
$11.5 billion (2020)
|
| gptkbp:stockSymbol |
MYL
|
| gptkbp:subsidiary |
gptkb:Mylan_N.V.
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.mylan.com
|